Fonterra said it was reviewing the US Food and Drug Administration's updated infant formula guidance to assess whether it opened an access supply opportunity.
Meanwhile, on its part in the delegation, the company said the US was an important market, particularly in terms of its value-add strategy.
"We have a number of sourcing, IP and investment partnerships in the US to support this strategy, and we are a leading supplier to active living customers there," Simon Tucker, director global sustainability, stakeholder affairs and trade, told the Herald.
Fonterra's provenance and sustainability credentials resonated with US customers and consumers, he said.
The delegation will visit the Langer Laboratory at the Massachusetts Institute of Technology, home of Fonterra's VitaKey partner in Boston.
VitaKey is a leader in innovative dairy nutrition. Delegates, led by agriculture and trade minister Damien O'Connor, will meet VitaKey co-founder and globally eminent bio-scientist Dr Robert Langer.
Tucker said Fonterra had more than 10 partnerships in the US, including with Motif FoodWorks and Land O'Lakes.
Its US activities are part of Fonterra's Amena business, which covers Africa, the Middle East, Europe, North Asia and the Americas.
US earnings are not broken out in Fonterra's 2021 annual report, which showed Amena had FY21 revenue of $7.3 billion, down 7 per cent on FY20, and ebit of $336 million.
Fonterra's total group revenue in FY21 was $20.9b, with reported net profit after tax of $599m.
The trade mission to the US, led by PM Jacinda Ardern, left last night.
Ardern said she would take the simple messages that New Zealand was open for business and recreation.
As the US opened up after the pandemic she wanted to make sure New Zealand was at the forefront of their minds. The US is New Zealand's third-largest market.